£299 + £30 phlebotomy fee

Empower yourself with the knowledge to stay ahead of health risks. The Cancer Profile Male Test is meticulously crafted to track biomarkers that are pivotal in the early detection of male-specific cancers.

  1. Digestive System Cancer Marker: Cancer Antigen 19-9 (CA 19-9)
  2. General Cancer Markers: Carcinoembryonic Antigen (CEA), Alpha-fetoprotein (AFP)
  3. Prostate Health Markers: Free Prostate-Specific Antigen (Free PSA), Total Prostate-Specific Antigen (Total PSA)
  1. General Cancer Markers: Carcinoembryonic Antigen (CEA) and Alpha-fetoprotein (AFP)
      • Carcinoembryonic Antigen (CEA):Role: CEA is a protein found in many types of cells but is associated with tumors in higher levels.
      • Applications: It’s most commonly associated with colorectal cancer but can also be elevated in other cancers like breast, lung, thyroid, and pancreatic cancers.
    • Monitoring: Used to monitor treatment efficacy and detect recurrences, particularly in colorectal cancer.
      • Alpha-fetoprotein (AFP):Purpose: AFP is a protein that is typically elevated in liver diseases, including liver cancer (hepatocellular carcinoma).
      • Other Associations: It can also be elevated in testicular cancer and certain benign liver conditions.
    • Use in Diagnosis: High levels of AFP can aid in the diagnosis and monitoring of these cancers, though they are not definitive on their own.
  2. Prostate Health Markers: Free Prostate-Specific Antigen (Free PSA) and Total Prostate-Specific Antigen (Total PSA)
      • Total Prostate-Specific Antigen (Total PSA):Function: PSA is a protein produced by both normal and cancerous prostate cells. High levels can indicate prostate cancer, benign prostate enlargement (BPH), or other prostate conditions.
    • Diagnostic Tool: Used as part of screening for prostate cancer, though elevated levels are not solely indicative of cancer.
      • Free Prostate-Specific Antigen (Free PSA):Purpose: Measuring the ratio of free PSA (not bound to proteins) to total PSA can help differentiate between prostate cancer and benign prostate conditions.
    • Application in Screening: A lower ratio of free PSA may indicate a higher risk of prostate cancer, aiding in more accurate diagnosis.
  1. Risk Assessment: Men with a family history of cancer or personal health concerns.
  2. Post-Diagnosis Monitoring: Those seeking to monitor known cancer markers for recurrence.
  3. Comprehensive Screening: Individuals desiring a detailed overview of male-specific cancer risks.
  4. Symptom Exploration: Men experiencing symptoms that may be indicative of cancer and require investigation.